These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 9237784)

  • 1. Relationships of C-peptide levels and the C-peptide/bloodsugar ratio with clinical/biochemical variables associated with insulin resistance in orally-treated, well-controlled type 2 diabetic patients.
    Relimpio F; Losada F; Pumar A; García de Pesquera F; Morales F; Acosta D; Astorga R
    Diabetes Res Clin Pract; 1997 Jun; 36(3):173-80. PubMed ID: 9237784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Albuminuria and 24-h ambulatory blood pressure in normoalbuminuric and microalbuminuric NIDDM patients. A longitudinal study.
    Nielsen S; Schmitz A; Poulsen PL; Hansen KW; Mogensen CE
    Diabetes Care; 1995 Nov; 18(11):1434-41. PubMed ID: 8722066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum ferritin as a component of the insulin resistance syndrome.
    Fernández-Real JM; Ricart-Engel W; Arroyo E; Balançá R; Casamitjana-Abella R; Cabrero D; Fernández-Castañer M; Soler J
    Diabetes Care; 1998 Jan; 21(1):62-8. PubMed ID: 9580307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycaemic control in type 2 diabetes: the impact of body weight, beta-cell function and patient education.
    Chan WB; Chan JC; Chow CC; Yeung VT; So WY; Li JK; Ko GT; Ma RC; Cockram CS
    QJM; 2000 Mar; 93(3):183-90. PubMed ID: 10751238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of regional adiposity to insulin resistance and serum triglyceride levels in nonobese Japanese type 2 diabetic patients.
    Taniguchi A; Nakai Y; Sakai M; Yoshii S; Hamanaka D; Hatae Y; Kawata M; Yamanouchi K; Okumura T; Doi K; Tokuyama K; Nagasaka S; Fukushima M
    Metabolism; 2002 May; 51(5):544-8. PubMed ID: 11979383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
    Chow CC; Tsang LW; Sorensen JP; Cockram CS
    Diabetes Care; 1995 Mar; 18(3):307-14. PubMed ID: 7555472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
    Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
    Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: U.K. Prospective Diabetes Study (UKPDS 55).
    Davis TM; Cull CA; Holman RR;
    Diabetes Care; 2001 Jul; 24(7):1167-74. PubMed ID: 11423497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM.
    Cusi K; Cunningham GR; Comstock JP
    Diabetes Care; 1995 Jun; 18(6):843-51. PubMed ID: 7555511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat mass.
    Fischer S; Hanefeld M; Haffner SM; Fusch C; Schwanebeck U; Köhler C; Fücker K; Julius U
    Acta Diabetol; 2002 Sep; 39(3):105-10. PubMed ID: 12357293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of socioeconomic status on cardiovascular risk factors in African-Americans at high risk for type II diabetes. Implications for syndrome X.
    Gaillard TR; Schuster DP; Bossetti BM; Green PA; Osei K
    Diabetes Care; 1997 May; 20(5):745-52. PubMed ID: 9135936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Roberts VL; Stewart J; Issa M; Lake B; Melis R
    Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin versus a combination of insulin and sulfonylurea in the treatment of NIDDM patients with secondary oral failure.
    Ravnik-Oblak M; Mrevlje F
    Diabetes Res Clin Pract; 1995 Oct; 30(1):27-35. PubMed ID: 8745203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of different insulin regimens in elderly patients with NIDDM.
    Wolffenbuttel BH; Sels JP; Rondas-Colbers GJ; Menheere PP; Nieuwenhuijzen Kruseman AC
    Diabetes Care; 1996 Dec; 19(12):1326-32. PubMed ID: 8941458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in amylin and amylin-like peptide concentrations and beta-cell function in response to sulfonylurea or insulin therapy in NIDDM.
    Rachman J; Payne MJ; Levy JC; Barrow BA; Holman RR; Turner RC
    Diabetes Care; 1998 May; 21(5):810-6. PubMed ID: 9589246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
    Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
    Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma lipoproteins and apolipoproteins in insulin-dependent and young non-insulin-dependent Arab women.
    al-Muhtaseb N; al-Yuosuf AR; Bajaj JS
    Acta Diabetol Lat; 1991; 28(1):61-9. PubMed ID: 1862693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Similar insulin sensitivity in NIDDM patients with normo- and microalbuminuria.
    Nielsen S; Schmitz O; Orskov H; Mogensen CE
    Diabetes Care; 1995 Jun; 18(6):834-42. PubMed ID: 7555510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: a 1-year follow-up.
    Clauson P; Karlander S; Steen L; Efendic S
    Diabet Med; 1996 May; 13(5):471-7. PubMed ID: 8737030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
    Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.